I Incyte Corp.
| Market Cap | $19.09B |
| P/E Ratio | 14.97 |
| Forward P/E | 11.09 |
| Dividend Yield | — |
| Beta | 0.86 |
| 52W Range | $55.17 - $110.57 |
| # Hedge Funds | 2 |
| Sector | Healthcare |
| Industry | Biotechnology |
Hedge Fund Ownership
| Investor 2 | % of Portfolio Weight of this stock in the investor's portfolio | Value Total dollar value of the position | Shares Number of shares held | Activity Portfolio change type: New, Increased, Decreased, or Sold |
|---|---|---|---|---|
| Harry Burn Sound Shore Management | 2.92% | $91.84M | 929,832 | Add 9.41% |
| Dodge & Cox Dodge & Cox | 0.71% | $1.31B | 13,261,742 | Reduce 4.81% |
Insider Trading
| Insider Name of the company insider who made the trade 30 | Type Purchase (buy) or Sale (sell) | Shares Number of shares traded | Price Price per share at time of transaction | Value Total dollar value of the transaction | Trade Date Date the transaction was executed | Filing Date Date the SEC filing was submitted |
|---|---|---|---|---|---|---|
| CAGNONI PABLO JPresident, R&D | Sale | 18,667 | $94.24 | $1.76M | 17 Mar 2026 | 17 Mar 2026 |
| CAGNONI PABLO JPresident, R&D | Sale | 18,668 | $100.91 | $1.88M | 19 Feb 2026 | 23 Feb 2026 |
| Issa Mohamed KhairieEVP, Head of US Oncology | Sale | 10,856 | $109.07 | $1.18M | 07 Jan 2026 | 08 Jan 2026 |
| Stein Steven HEVP & Chief Medical Officer | Sale | 15,634 | $101.70 | $1.59M | 05 Jan 2026 | 07 Jan 2026 |
| Steven H SteinEVP & Chief Medical Officer | Sale | 15,634 | $101.70 | $1.59M | 05 Jan 2026 | 07 Jan 2026 |
| Tray ThomasPrincipal Accounting Officer | Sale | 2,774 | $100.00 | $277.40K | 19 Dec 2025 | 22 Dec 2025 |
| Tray ThomasPrincipal Accounting Officer | Sale | 600 | $98.25 | $58.95K | 18 Dec 2025 | 22 Dec 2025 |
| Morrissey Michael JamesEVP, Head of Tech. Operations | Sale | 4,323 | $97.26 | $420.45K | 17 Dec 2025 | 18 Dec 2025 |
| Morrissey Michael JamesEVP, Head of Tech. Operations | Sale | 53,175 | $97.29 | $5.17M | 16 Dec 2025 | 18 Dec 2025 |
| Morrissey Michael JamesEVP, Head of Tech. Operations | Sale | 833 | $97.42 | $81.15K | 16 Dec 2025 | 18 Dec 2025 |
| Mayes Patrick AEVP & Chief Scientific Officer | Sale | 255 | $94.94 | $24.21K | 11 Dec 2025 | 12 Dec 2025 |
| Mayes Patrick AEVP & Chief Scientific Officer | Sale | 5,553 | $95.58 | $530.76K | 10 Dec 2025 | 12 Dec 2025 |
| Stein Steven HEVP & Chief Medical Officer | Sale | 20,105 | $102.51 | $2.06M | 02 Dec 2025 | 03 Dec 2025 |
| Steven H SteinEVP & Chief Medical Officer | Sale | 20,105 | $102.51 | $2.06M | 02 Dec 2025 | 03 Dec 2025 |
| Stein Steven HEVP & Chief Medical Officer | Sale | 2,559 | $102.96 | $263.47K | 01 Dec 2025 | 03 Dec 2025 |
| Steven H SteinEVP & Chief Medical Officer | Sale | 2,559 | $102.96 | $263.47K | 01 Dec 2025 | 03 Dec 2025 |
| Tray ThomasPrincipal Accounting Officer | Sale | 600 | $103.00 | $61.80K | 24 Nov 2025 | 25 Nov 2025 |
| Thomas TrayPrincipal Accounting Officer | Sale | 600 | $103.00 | $61.80K | 24 Nov 2025 | 25 Nov 2025 |
| Tray ThomasPrincipal Accounting Officer | Sale | 169 | $102.00 | $17.24K | 21 Nov 2025 | 25 Nov 2025 |
| Thomas TrayPrincipal Accounting Officer | Sale | 169 | $102.00 | $17.24K | 21 Nov 2025 | 25 Nov 2025 |
| Denton Sheila A.EVP & General Counsel | Sale | 278 | $104.36 | $29.01K | 17 Nov 2025 | 19 Nov 2025 |
| Sheila A. DentonEVP & General Counsel | Sale | 278 | $104.36 | $29.01K | 17 Nov 2025 | 19 Nov 2025 |
| Hoppenot Herve | Sale | 187,500 | $105.46 | $19.77M | 10 Nov 2025 | 12 Nov 2025 |
| Stein Steven HEVP & Chief Medical Officer | Sale | 5,233 | $102.20 | $534.81K | 05 Nov 2025 | 07 Nov 2025 |
| Denton Sheila A.EVP & General Counsel | Sale | 598 | $101.36 | $60.61K | 04 Nov 2025 | 06 Nov 2025 |
| Sheila A. DentonEVP & General Counsel | Sale | 598 | $101.36 | $60.61K | 04 Nov 2025 | 06 Nov 2025 |
| Heeson LeeEVP, Head of Incyte Intl | Sale | 3,074 | $94.02 | $289.02K | 03 Nov 2025 | 05 Nov 2025 |
| Lee HeesonEVP, Head of Incyte Intl | Sale | 3,074 | $94.02 | $289.02K | 03 Nov 2025 | 05 Nov 2025 |
| Denton Sheila A.EVP & General Counsel | Sale | 277 | $85.13 | $23.58K | 15 Oct 2025 | 17 Oct 2025 |
| Sheila A. DentonEVP & General Counsel | Sale | 277 | $85.13 | $23.58K | 15 Oct 2025 | 17 Oct 2025 |
Frequently Asked Questions
What is INCY stock price today?
Incyte Corp. (INCY) is currently trading at $95.93. The stock has a 52-week range of $55.17 to $110.57 and a market capitalization of $19.09B.
Is INCY a good stock to buy in 2026?
Incyte Corp. has a P/E ratio of 15.0 (forward P/E: 11.1), a dividend yield of none, and 1-year performance of +53.6%. 2 hedge funds hold this stock. Review the fundamentals and ownership data above to make an informed decision.
Are insiders buying or selling INCY stock?
There have been 30 insider transactions for INCY in recent months. Insider buys can signal management confidence, while sales may reflect diversification or personal financial planning. Check the Insider Trading section above for details.
How has INCY stock performed over the past year?
Incyte Corp. (INCY) has returned +53.6% over the past 12 months. The stock traded between $55.17 and $110.57 during this period, and is currently at $95.93.
Which hedge funds own INCY (Incyte Corp.)?
2 tracked hedge funds currently hold INCY in their portfolios as of the latest 13F filings. See the ownership table above for the complete list.
What is INCY's market cap and valuation?
Incyte Corp. (INCY) has a market capitalization of $19.09B. The trailing P/E ratio is 15.0 and forward P/E is 11.1. The stock is classified in the Healthcare sector.
What is INCY's revenue and profitability?
Incyte Corp. reported revenue of $5.14B with net income of $1.29B and a profit margin of 0.25%. The stock has a beta of 0.86.
What sector is INCY in and who are its biggest institutional holders?
Incyte Corp. (INCY) operates in the Healthcare sector. It is held by 2 tracked hedge funds. See the ownership table above for the complete list.